JP2019532631A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019532631A5 JP2019532631A5 JP2019515292A JP2019515292A JP2019532631A5 JP 2019532631 A5 JP2019532631 A5 JP 2019532631A5 JP 2019515292 A JP2019515292 A JP 2019515292A JP 2019515292 A JP2019515292 A JP 2019515292A JP 2019532631 A5 JP2019532631 A5 JP 2019532631A5
- Authority
- JP
- Japan
- Prior art keywords
- virus
- seq
- peptide
- tumor
- modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022197406A JP2023029997A (ja) | 2016-09-27 | 2022-12-09 | エンベロープウイルスの非遺伝的改変 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1616365.1A GB201616365D0 (en) | 2016-09-27 | 2016-09-27 | Non-genetic modification of enveloped viruses |
| GB1616365.1 | 2016-09-27 | ||
| PCT/EP2017/072366 WO2018059896A1 (en) | 2016-09-27 | 2017-09-06 | Non-genetic modification of enveloped viruses |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022197406A Division JP2023029997A (ja) | 2016-09-27 | 2022-12-09 | エンベロープウイルスの非遺伝的改変 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019532631A JP2019532631A (ja) | 2019-11-14 |
| JP2019532631A5 true JP2019532631A5 (enExample) | 2020-10-08 |
| JP7258746B2 JP7258746B2 (ja) | 2023-04-17 |
Family
ID=57539741
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019515292A Active JP7258746B2 (ja) | 2016-09-27 | 2017-09-06 | エンベロープウイルスの非遺伝的改変 |
| JP2022197406A Pending JP2023029997A (ja) | 2016-09-27 | 2022-12-09 | エンベロープウイルスの非遺伝的改変 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022197406A Pending JP2023029997A (ja) | 2016-09-27 | 2022-12-09 | エンベロープウイルスの非遺伝的改変 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10982194B2 (enExample) |
| EP (1) | EP3519565A1 (enExample) |
| JP (2) | JP7258746B2 (enExample) |
| KR (1) | KR102599401B1 (enExample) |
| CN (1) | CN109890957A (enExample) |
| AU (2) | AU2017337753B2 (enExample) |
| BR (1) | BR112019005825A2 (enExample) |
| CA (1) | CA3035104A1 (enExample) |
| GB (1) | GB201616365D0 (enExample) |
| RU (1) | RU2760521C2 (enExample) |
| WO (1) | WO2018059896A1 (enExample) |
| ZA (1) | ZA201902388B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201907413D0 (en) * | 2019-05-24 | 2019-07-10 | Univ Helsinki | Viral vector |
| WO2020252039A1 (en) * | 2019-06-12 | 2020-12-17 | Biontech Us Inc. | Neoantigen compositions and uses thereof |
| US20220305099A1 (en) * | 2019-08-27 | 2022-09-29 | Turnstone Biologics Corp. | Methods for inducing an immune response against neoantigens |
| GB202013834D0 (en) * | 2020-09-03 | 2020-10-21 | Valo Therapeutics Oy | PeptiVAX therapy |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1257286C (zh) | 1998-08-27 | 2006-05-24 | 森泰莱昂公司 | 用于递送异源基因的定向腺病毒载体 |
| MXPA01005389A (es) * | 1998-11-30 | 2003-03-27 | Cytos Biotechnology Ag | Presentacion molecular ordenada de antigenos, metodos de preparacion y uso. |
| IL145899A0 (en) * | 1999-04-15 | 2002-07-25 | Pro Virus Inc | Treatment of neoplasms with viruses |
| CN100352921C (zh) | 1999-05-06 | 2007-12-05 | 威克福雷大学 | 用于鉴定引起免疫反应的抗原的组合物和方法 |
| CN101024842A (zh) * | 2001-11-07 | 2007-08-29 | 曼康公司 | 编码靶相关抗原表位的表达载体及其设计方法 |
| GB0203285D0 (en) * | 2002-02-12 | 2002-03-27 | Brown Susanne M | An herpes simplex virus complex |
| WO2004000220A2 (en) | 2002-06-21 | 2003-12-31 | Genetix Pharmaceuticals, Inc. | Methods for purifying viral particles for gene therapy |
| US20070243170A1 (en) * | 2002-10-07 | 2007-10-18 | The University Of Chicago | Targeting of Herpes Simplex Virus to Specific Receptors |
| AU2004224761A1 (en) * | 2003-03-26 | 2004-10-07 | Cytos Biotechnology Ag | HIV-peptide-carrier-conjugates |
| HRP20120845T1 (hr) * | 2003-07-02 | 2012-11-30 | Innate Pharma | Protutijela za pan-kir2dl nk-receptor i njihova uporaba u dijagnostici i lijeäśenju |
| WO2005060541A2 (en) | 2003-12-01 | 2005-07-07 | Wisconsin Alumni Research Foundation | Peptides and methods for inducing cellular resistance to infection |
| KR101157694B1 (ko) * | 2003-12-17 | 2012-06-20 | 와이어쓰 엘엘씨 | 면역원성 펩티드 캐리어 컨쥬게이트 및 이의 제조 방법 |
| EP1921149A1 (en) * | 2006-11-13 | 2008-05-14 | AEterna Zentaris GmbH | Microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins, process of manufacturing and uses thereof |
| JP2008136381A (ja) * | 2006-11-30 | 2008-06-19 | Japan Health Science Foundation | 改変型アデノウイルスベクター及びその作製方法 |
| WO2009117656A2 (en) | 2008-03-21 | 2009-09-24 | Vectorlogics,Inc. | Capsid-incorporated antigen for novel adenovirus vaccine |
| NO2700405T3 (enExample) * | 2008-05-29 | 2018-09-01 | ||
| EP2349296B1 (en) * | 2008-08-21 | 2017-04-05 | Ottawa Hospital Research Institute | Engineered synergistic oncolytic viral symbiosis |
| ES2335077B1 (es) | 2008-12-30 | 2011-02-02 | Instituto Aragones De Ciencias De La Salud | Formulaciones para el recubrimiento y transporte de diversos elementos hacia los tumores. |
| US8609392B2 (en) * | 2009-05-12 | 2013-12-17 | Transgene S.A. | Method for orthopoxvirus production and purification |
| US20130243731A1 (en) | 2010-09-24 | 2013-09-19 | Oncos Therapeutics Oy | Oncolytic adenoviral vectors coding for monoclonal anti-ctla-4 antibodies |
| US20140140962A1 (en) | 2011-04-29 | 2014-05-22 | The Research Foundation Of State University Of New York | Viruses modified with unnatural moieties and methods of use thereof |
| US20140349944A1 (en) * | 2013-05-23 | 2014-11-27 | Musc Foundation For Research Development | Chaperone-based integrin inhibitors for the treatment of cancer and inflammatory diseases |
| RS65104B1 (sr) | 2013-08-22 | 2024-02-29 | Univ Pittsburgh Commonwealth Sys Higher Education | Onkolitičke imunoterapije |
| BR112016009465A8 (pt) * | 2013-10-28 | 2018-01-30 | Univ Pittsburgh Commonwealth Sys Higher Education | vetor de hsv oncolítico. |
| US10799568B2 (en) | 2014-05-19 | 2020-10-13 | Valo Therapeutics Oy | Modified adenoviruses for cancer vaccines development |
-
2016
- 2016-09-27 GB GBGB1616365.1A patent/GB201616365D0/en not_active Ceased
-
2017
- 2017-09-06 WO PCT/EP2017/072366 patent/WO2018059896A1/en not_active Ceased
- 2017-09-06 KR KR1020197012062A patent/KR102599401B1/ko active Active
- 2017-09-06 CA CA3035104A patent/CA3035104A1/en active Pending
- 2017-09-06 BR BR112019005825-7A patent/BR112019005825A2/pt not_active Application Discontinuation
- 2017-09-06 JP JP2019515292A patent/JP7258746B2/ja active Active
- 2017-09-06 US US16/337,220 patent/US10982194B2/en active Active
- 2017-09-06 CN CN201780056649.7A patent/CN109890957A/zh active Pending
- 2017-09-06 EP EP17765150.2A patent/EP3519565A1/en active Pending
- 2017-09-06 RU RU2019110407A patent/RU2760521C2/ru active
- 2017-09-06 AU AU2017337753A patent/AU2017337753B2/en active Active
-
2019
- 2019-04-15 ZA ZA2019/02388A patent/ZA201902388B/en unknown
-
2022
- 2022-12-09 JP JP2022197406A patent/JP2023029997A/ja active Pending
-
2023
- 2023-09-29 AU AU2023237201A patent/AU2023237201B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019532631A5 (enExample) | ||
| CY1124275T1 (el) | Vsv/ndv υβριδικοι ιοι για την ογκολυτικη θεραπεια του καρκινου | |
| Zamarin et al. | Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions | |
| Swiecki et al. | BST-2/tetherin: structural biology, viral antagonism, and immunobiology of a potent host antiviral factor | |
| JP2017522025A5 (enExample) | ||
| JP2019513118A5 (enExample) | ||
| US20210169956A1 (en) | Increased activity of oncolytic newcastle disease virus | |
| JP2014532649A5 (enExample) | ||
| JP2019526580A5 (enExample) | ||
| RU2017103162A (ru) | Онколитический вирус для экспрессии модуляторов иммунологических контрольных точек | |
| JP2019508045A5 (enExample) | ||
| JP2010523471A5 (enExample) | ||
| US10604741B2 (en) | Compositions and methods for enhancing virus replication | |
| JP2023542297A5 (enExample) | ||
| JP2012525410A5 (enExample) | ||
| JP2020533411A5 (enExample) | ||
| RU2019110407A (ru) | Негенетическая модификация оболочечных вирусов | |
| TW202227126A (zh) | 異源初免加強疫苗 | |
| FI3448879T3 (fi) | Claudin-6 -peptidejä | |
| Sharma et al. | PTAP motif duplication in the p6 Gag protein confers a replication advantage on HIV-1 subtype C | |
| JP2023529839A5 (enExample) | ||
| JP2011529683A5 (enExample) | ||
| JP2023536466A5 (enExample) | ||
| Parzych et al. | Influenza virus specific CD8+ T cells exacerbate infection following high dose influenza challenge of aged mice | |
| JP2024534189A5 (enExample) |